HK Stock Market Move | METIS TECHBIO-P (07666) rose over 8% after earnings, with six-month revenue exceeding 47% of last year's total. The company's commercialization milestones are accelerating.

METIS TECHBIO-P (07666) saw its stock rise by over 8% after the performance announcement, and as of the time of writing, it is up 7.97%, priced at HK$14.9, with a trading volume of HK$16.821 million. On the news front, on August 25, Ji Tai Technology disclosed its interim performance for 2026. During the reporting period, the company achieved an operating revenue of 154 million yuan, a remarkable year-on-year increase of 13,339%, exceeding last year's total revenue by 47%. At the same time, the company's financial structure continued to optimize: R&D expenditure for the current period increased by 48.1% year-on-year to 172 million yuan; adjusted net loss narrowed significantly by 56.4% to 51.1 million yuan; current cash reserves stood at 3.025 billion yuan, and the debt-to-asset ratio improved from 19.3% at the end of 2025 to 9%. As the commercialization results of NanoForge enter a concentrated release phase, Ji Tai's core innovative value is expected to continue to gain dual validation from global industries and capital markets. In the first half of 2026, NanoForge's platform capabilities received substantial recognition from international professional investment institutions and leading multinational pharmaceutical companies, achieving consecutive commercial milestones that further validated NanoForge's ability to continuously produce globally valuable innovative assets. It is noteworthy that recently, the world's first clinically validated mRNA therapeutic cancer vaccine confirmed the feasibility and commercial value of mRNA technology for cancer treatment. Against this backdrop, the NanoForge platform, which has mRNA tumor vaccine R&D capabilities combined with LNP delivery potential, received recognition in the secondary market, driving the company's stock price to rise by over 35% in a single day.